Back to results
US 10,894,833 B2Granted
Agents, uses and methods for treatment
AssigneeH. Lundbeck A/S
InventorsLars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
Claims4
An anti-sortilin antibody, or antigen-binding fragment thereof, comprising:
- (1) a. a heavy chain variable domain CDR1 comprising SEQ ID NO:61;
- b. a heavy chain variable domain CDR2 comprising SEQ ID NO:62;
- c. a heavy chain variable domain CDR3 comprising SEQ ID NO:63;
- d. a light chain variable domain CDR1 comprising SEQ ID NO:64;
- e. a light chain variable domain CDR2 comprising SEQ ID NO:65;
- and
- f. a light chain variable domain CDR3 comprising SEQ ID NO:66, or
- (2) a heavy chain variable domain comprising SEQ ID NO:129;
- and
- a light chain variable domain comprising SEQ ID NO:130.
7 more elements
Dependencies are inferred from the claim text.